SHIRLEY, NY, January 29, 2026 /24-7PressRelease/ -- Drug developers are increasingly looking beyond single‑target biology and toward the complex interaction webs that drive disease. Traditional in vitro assays often fall short when researchers need to capture interactions in a native intracellular environment, especially for membrane proteins or variant libraries. That gap has pushed Y2H technologies—once considered a workhorse method—back into the spotlight.

Creative Biolabs can provide many types of two-hybrid services, such as yeast two-hybrid (Y2H), mammalian two-hybrid (M2H), bacterial two-hybrid (B2H), and reverse yeast two-hybrid (rYTH), for global clients to identify the role of protein-protein interactions in biological systems.

To make the system more useful, their scientists have refined the two-hybrid platform. "We use gateway cloning technology, which allows us to quickly transfer DNA sequences encoding proteins of interest into different vector systems compatible with the two-hybrid assay, streamlining the setup process," said a scientist at Creative Biolabs.

According to a Principal Scientist, U.S. biotech, "We were finally able to screen membrane proteins that had stalled our project for months," said a Principal Scientist, U.S. biotech

"The reverse Y2H platform gave us a clean readout on disruptive mutations. It clarified our drug mechanism faster than expected," said a Group Leader, European research institute

A Broader Technology Ecosystem Behind the Scenes
In addition to the solutions mentioned above, Creative Biolabs also offers broader discovery services to identify ideal binders tailored to the specific needs of research projects, whether they involve antibodies, peptides, or small molecules. The company highlights its strengths in binder discovery through highly precise identification technologies, a wide range of discovery platforms, fully customized project strategies, and fast, reliable results that keep research moving efficiently.

Looking Ahead: Interaction Biology as a Driver of Innovation
As protein interaction research continues to expand—from oncology to synthetic biology—Creative Biolabs sees its enhanced platform as part of a broader shift toward more integrated, mechanism‑aware discovery tools.

"Protein interactions shape nearly every biological process," said a spokesperson for Creative Biolabs. "Our goal is to give researchers technologies that not only generate data but help them understand the story behind that data."

Learn more details on Creative Biolabs' technology platforms and yeast two‑hybrid services, please visit https://www.creative-biolabs.com/.

About Creative Biolabs
Creative Biolabs, a USA-based biotechnology company, specializes in advanced binder discovery and engineering, leveraging diverse technology platforms and tailored workflows to support innovative antibody, peptide, and small‑molecule research across a wide range of applications.

This contant was orignally distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Creative Biolabs Pushes Into Next‑Gen Interaction Biology With Yeast Two‑Hybrid Platforms.